

	<b>M22 - OLANZAPINE</b>	
	MEDICATION STANDING ORDER	
Version date: 2023-07-25	Effective date: 2023-09-19 (0700 hrs)	

INDICATIONS
<ul style="list-style-type: none"> <li>Known or suspected methamphetamine psychosis</li> </ul>

CONTRAINDICATIONS
<ul style="list-style-type: none"> <li>Uncooperative patient</li> <li>Hypotension</li> <li>Seizure or acute neurological deficit</li> <li>Chest pain or dyspnea suspicious for acute cardiac syndrome (ACS)</li> </ul>

ROUTE (WORK SCOPE)	INITIAL DOSE	REPEAT DOSE
ORAL (PCP & ABOVE)	12 years & older - 10 mg	None

NOTES
<ol style="list-style-type: none"> <li>Patients who have taken methamphetamine may rapidly develop extreme paranoia and demonstrate violent behavior with enhanced physical strength. After the onset of psychosis, forced medication administration may be difficult. Administration of olanzapine while the patient is cooperative may lessen the severity of psychotic symptoms.</li> <li>Olanzapine is a chemical restraint and any regional restraint policy should be followed when administering.</li> </ol>

APPROVED BY	
	
Medical Director - Provincial EMS/PT	Associate Medical Director – Provincial EM/SPT

**VERSION CHANGES (refer to X08 for change tracking)**

- Revised administration table presents information for scope / route / dose more clearly